Novo Nordisk A/ S stock (DK0062498333): Wegovy and Ozempic keep growth story in focus

Novo Nordisk A/S remains one of the most closely watched healthcare stocks globally as demand for its obesity and diabetes treatments Wegovy and Ozempic continues to influence revenue growth, profitability and market expectations. Investors are monitoring how the company manages capacity expansion, pricing dynamics and competition in the fast-growing GLP?1 drug class.

Recently, Novo Nordisk has continued to emphasize strong demand trends for its obesity franchise and ongoing investments in manufacturing expansion, while markets assess how these factors could shape earnings trajectories in the coming years, according to public company statements and major financial media coverage in spring 2025 and early 2026.

As of: 09.06.2026

By the editorial team – specialized in equity coverage.

Novo Nordisk A/S: core business model

Novo Nordisk A/S focuses on therapeutic areas with chronic, high-prevalence diseases, primarily diabetes and obesity, complemented by rare disease treatments such as hemophilia and growth hormone therapies. The company generates most of its revenue from prescription medicines that are used over long periods, creating recurring demand and relatively high visibility for its top line.

Within diabetes care, Novo Nordisk has historically been a leader in insulin and GLP?1 agonists, developing injectable and oral formulations designed to improve blood sugar control and, more recently, support weight loss. This combination of metabolic efficacy and weight reduction has helped differentiate its newer GLP?1-based products from traditional insulin regimens in many treatment guidelines.

Obesity care has become a second major strategic pillar alongside diabetes. The company markets GLP?1-based treatments approved for chronic weight management, with Wegovy as a flagship brand. These medicines target patients with obesity and weight-related comorbidities, a population that health systems increasingly recognize as requiring long-term medical management rather than short-term dieting alone.

Novo Nordisk’s rare disease segment includes therapies for hemophilia, rare endocrine disorders and growth hormone deficiencies. While smaller than the diabetes and obesity franchises, this segment can provide high-margin revenue and helps diversify the company’s therapeutic footprint beyond metabolic diseases.

The core business model therefore rests on discovering, developing, and commercializing biologic and small-molecule drugs that address chronic metabolic and rare conditions, supported by significant investments in clinical research, manufacturing scale and global commercial infrastructure. Patents and regulatory exclusivities play a central role in protecting pricing power for key drugs during their lifecycle.

Main revenue and product drivers for Novo Nordisk A/S

The main revenue driver for Novo Nordisk A/S in recent years has been its portfolio of GLP?1 agonists for type 2 diabetes and obesity. Ozempic, a once?weekly injectable GLP?1 treatment for diabetes, has become a major global brand, while Wegovy, based on the same active ingredient semaglutide but indicated for chronic weight management, has quickly gained traction in obesity care in markets where it is approved.

These products build on earlier GLP?1 therapies from the company, but semaglutide-based drugs have stood out due to robust clinical data on blood sugar control and weight loss. Their success has helped drive a shift in the company’s revenue mix from older insulin products toward newer GLP?1 therapies with higher price points and, in many cases, more favorable reimbursement in markets that prioritize outcomes-based care.

Insulin products nonetheless remain important. Novo Nordisk retains a significant share of the global insulin market with various formulations, including long-acting and rapid-acting analogs. These treatments continue to support millions of patients with type 1 and type 2 diabetes worldwide, particularly in regions where GLP?1 uptake is still emerging or where cost considerations favor established insulin regimens.

In obesity care, Wegovy’s growth reflects both latent patient demand and changing attitudes among physicians and payers regarding chronic obesity treatment. As clinical data demonstrate benefits beyond weight loss, including potential improvements in cardiovascular outcomes in some studies, payers and guideline bodies in major markets have reassessed how these medicines might reduce long-term healthcare costs.

On the rare disease side, products for hemophilia and growth disorders contribute a smaller but strategically relevant share of revenue. They typically command premium pricing and serve highly specialized patient populations, which can reduce competitive intensity compared with broader metabolic indications.

Geographically, the United States remains Novo Nordisk’s largest single market by revenue, driven by relatively high drug prices and strong demand for GLP?1 therapies among patients with commercial insurance and public coverage. Europe, Japan and other developed markets also provide substantial revenue, while emerging markets contribute additional volume growth, particularly for insulin and established diabetes treatments.

Industry trends and competitive position

Novo Nordisk A/S operates in a pharmaceutical segment experiencing structural growth, particularly in obesity and diabetes. Rising global obesity rates and the increasing prevalence of type 2 diabetes have created a large and expanding patient pool, which in turn supports demand for effective long-term pharmacologic management options.

Within this environment, GLP?1 agonists have emerged as one of the most dynamic drug classes. These medicines target pathways related to appetite, satiety and glucose regulation, which can lead to both weight loss and improved glycemic control. Novo Nordisk’s semaglutide franchise has become central to this trend, helping the company secure a leading position in the GLP?1 market and establishing strong brand recognition among physicians and patients.

Competition has intensified as peers develop and launch their own GLP?1 and related incretin-based therapies, some exploring dual or triple agonist mechanisms designed to further enhance weight loss and metabolic outcomes. Competitors are working to expand indications and improve convenience through new formulations, such as oral or longer-acting injectables, which could alter competitive dynamics over time.

Against this backdrop, Novo Nordisk invests heavily in clinical research to expand the evidence base for its existing products and explore additional indications, including cardiovascular and renal outcomes. Positive outcomes data can support broader reimbursement, help differentiate products in crowded markets and potentially extend the commercial life of key brands through label expansions.

Manufacturing capacity has become a critical strategic issue. The rapid uptake of GLP?1 therapies has highlighted supply constraints across the industry, and Novo Nordisk has announced substantial capital expenditures to expand production of active pharmaceutical ingredients, fill?finish operations and device components. Successfully executing these investments is important to align supply with demand and reduce bottlenecks that can limit sales growth.

Payers and policymakers are also shaping the industry landscape. In the United States, debates over drug pricing, particularly for high-cost chronic therapies, may influence net pricing, rebate structures and formulary access for GLP?1 drugs. Novo Nordisk’s ability to navigate these discussions while maintaining attractive economics for its products is a key element of its competitive position.

Why Novo Nordisk A/S matters for US investors

For US investors, Novo Nordisk A/S offers exposure to several long-term healthcare themes, including rising obesity rates, a growing population of patients with type 2 diabetes and ongoing innovation in metabolic and cardiovascular medicine. The company’s ADRs trade on the New York Stock Exchange under the ticker NVO, providing convenient access through US brokerage accounts.

The US market itself is a central driver of Novo Nordisk’s financial performance, given its size, pricing environment and high adoption of innovative therapies. As a result, trends in US healthcare policy, reimbursement and competition can have a direct impact on the company’s revenue, margins and earnings trajectory.

In addition, Novo Nordisk’s scale and specialization in metabolic disease place it among the larger global pharmaceutical groups with a focused portfolio rather than a fully diversified pipeline. This focus can amplify both the opportunities and the risks associated with developments in GLP?1 and related classes, which investors may weigh when considering the stock in the context of broader healthcare or global equity allocations.

Conclusion

Novo Nordisk A/S stands at the center of structural shifts in obesity and diabetes treatment, with GLP?1 therapies such as Ozempic and Wegovy driving much of the company’s current growth and investor attention. The business model combines long-term chronic disease management, high research intensity and global commercial reach, characteristics that can support recurring revenue and sustained product innovation. At the same time, the company operates in a competitive and politically sensitive area of the pharmaceutical market, where manufacturing scale, outcomes data and pricing discussions in key regions such as the United States can significantly influence future performance. For US investors, the stock represents a targeted way to gain exposure to the evolution of metabolic disease treatment within the broader healthcare sector.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.